What Is Eccentric Hypertrophy?

When I tell a patient their echocardiogram shows eccentric hypertrophy, the first reaction is usually confusion. The word hypertrophy sounds like the heart is getting stronger, but eccentric hypertrophy is actually a sign that the heart has been working under stress and has remodeled itself in a specific way. As a cardiologist in Encinitas, I see this finding often on echocardiograms, and it carries real prognostic weight that every patient deserves to understand.

This article walks you through what eccentric hypertrophy is, how it differs from concentric hypertrophy, what causes it, what it predicts about your future cardiac health, and what we can do about it.

What Eccentric Hypertrophy Actually Means

Eccentric hypertrophy is a specific pattern of left ventricular remodeling. Three features define it: the total muscle mass of the left ventricle is increased, the chamber itself is enlarged, and the wall thickness relative to chamber size is normal or reduced. Cardiologists use a measurement called relative wall thickness, or RWT, to quantify this. In eccentric hypertrophy, RWT is below 0.32, meaning the chamber has grown disproportionately compared to the walls.

Contrast this with concentric hypertrophy, where the walls thicken disproportionately to chamber size. The chamber may stay the same size or even shrink, while the muscle walls grow thicker. Both patterns involve increased LV mass, but they arise from different stresses and carry different risks.

The short version: concentric hypertrophy is the heart responding to pressure, and eccentric hypertrophy is the heart responding to volume.

The Physiology: Why the Heart Remodels This Way

Every heart muscle cell is built from repeating units called sarcomeres. When the ventricle is exposed to chronically high diastolic wall stress, meaning the chamber is being stretched during filling, the cells respond by adding sarcomeres end to end. This lengthens each cell and, over time, enlarges the chamber. Absolute wall thickness may rise modestly, but relative to the new larger chamber, the walls look thin.

Pressure overload works differently. When the heart has to push against a high resistance, as in aortic stenosis or severe hypertension, sarcomeres are added in parallel rather than in series. The walls thicken, but the chamber stays the same size or shrinks. This is the concentric pattern.

The remodeling process is adaptive in the short term but maladaptive over the long term. The enlarged chamber generates more wall stress, which drives more remodeling, which eventually transitions to fibrosis, impaired contraction, and clinical heart failure.

What Causes Eccentric Hypertrophy

The most common driver is chronic volume overload. The prototypical cause is long-standing mitral regurgitation, where blood sloshes backward into the left atrium during every contraction, forcing the ventricle to handle a larger volume than normal. Chronic aortic regurgitation does the same, though the pattern is often mixed because the ventricle also has to generate more pressure. High-output states like severe anemia, thyrotoxicosis, or arteriovenous fistulas can produce eccentric remodeling as well.

The second big category is primary myocardial dysfunction. In dilated cardiomyopathy, the muscle weakens and the chamber dilates in response. In advanced systolic heart failure, particularly when the ejection fraction falls, the chamber enlarges and the relative wall thickness drops. Hypertensive heart disease, which typically starts as concentric hypertrophy, can decompensate into an eccentric pattern when the ventricle can no longer keep up with pressure demands.

Eccentric hypertrophy is actually the most common abnormal left ventricular geometry in patients with hypertension, which surprises many people because we think of hypertension as causing thick walls. Obesity and metabolic disease also contribute, likely through a combination of volume loading, insulin resistance effects on the myocardium, and concurrent sleep apnea.

Why This Matters: The Prognostic Weight of Eccentric Hypertrophy

When patients learn they have abnormal LV geometry on their echo, they want to know what it means for their future. The data here are sobering, and this is why I take this finding seriously in clinic.

The Multi-Ethnic Study of Atherosclerosis, published in 2022, followed patients for fifteen years and found that eccentric LVH carried the highest mortality risk of any abnormal LV geometry. All-cause mortality was 2.58 times higher than in patients with normal geometry, compared with 1.84 times higher for concentric hypertrophy. Fifteen-year mortality was 56.6 percent in the eccentric group, 47.4 percent in the concentric group, and 21.7 percent in patients with normal geometry.

The Framingham Heart Study showed a similar pattern for heart failure. Eccentric LVH carried the greatest risk of incident heart failure, with a hazard ratio of 1.89 compared to normal geometry. Patients with eccentric hypertrophy are particularly predisposed to heart failure with reduced ejection fraction, or HFrEF, with a hazard ratio of 2.23. Concentric hypertrophy, in contrast, predicts heart failure with preserved ejection fraction, or HFpEF.

In patients with chronic kidney disease and hypertension, both patterns predict poor cardiovascular and renal outcomes, with hazard ratios in the 2.3 to 2.8 range.

The takeaway is that eccentric hypertrophy is not a benign echo finding. It reflects real, measurable stress on the left ventricle and predicts real, measurable clinical events.

What We Do About It

The good news is that LV remodeling is partially reversible. The approach is cause-specific, and this is where careful cardiology evaluation pays off.

If the driver is valvular regurgitation, the timing of valve repair or replacement becomes the central question. Modern guidelines emphasize operating before the ventricle dilates past the point of recovery. For mitral regurgitation, we watch LV size and ejection fraction closely and intervene before irreversible changes set in. MitraClip and other transcatheter approaches have expanded the options for patients who are not ideal surgical candidates.

If the driver is hypertension, aggressive blood pressure control can reverse remodeling. ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists have particular evidence for reducing LV mass. Getting systolic pressure below 130 mmHg is usually the target, though we individualize based on age and other conditions.

If the driver is heart failure with reduced ejection fraction, guideline-directed medical therapy is transformative. The four pillars of HFrEF therapy, which include ARNI or ACE/ARB, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, consistently reverse remodeling and improve survival. Starting these medications early and titrating to target doses is the single most impactful thing a patient with eccentric hypertrophy and low EF can do.

Weight loss, sleep apnea treatment, diabetes control, and regular aerobic exercise all contribute as well. These are not small interventions. In patients with obesity-related cardiac remodeling, sustained weight loss can demonstrably shrink the heart chamber and improve wall geometry.

What to Ask Your Cardiologist

If an echo report mentions eccentric hypertrophy, a few questions are worth raising at your next appointment. What is driving it in your specific case? Is there an active valvular lesion that needs to be followed or treated? What is your ejection fraction, and has it changed over time? Are you on optimal medical therapy for the underlying cause? When should the echo be repeated to track progress?

The most important message is that this is actionable information. We can identify the cause, we can treat it, and in many cases we can reverse at least part of the remodeling. I see this in practice regularly, and I would rather catch eccentric hypertrophy early and treat it aggressively than find out about it after a first hospitalization for heart failure.

Frequently Asked Questions

Is eccentric hypertrophy the same thing as an enlarged heart?

Not exactly, though the terms overlap. An enlarged heart on a chest X-ray is a radiographic finding that can reflect many things. Eccentric hypertrophy is a specific echocardiographic pattern where the left ventricle has both increased mass and a dilated chamber with a low relative wall thickness. An enlarged heart on imaging often does show eccentric hypertrophy when we look closer with echo.

Can eccentric hypertrophy go away?

Partially, yes. With treatment of the underlying cause, the left ventricle can remodel back toward a more normal size and geometry. Mitral valve repair for severe regurgitation, aggressive blood pressure control for hypertension, and guideline-directed medical therapy for heart failure all promote reverse remodeling. The earlier we intervene, the more recovery we typically see.

Do athletes get eccentric hypertrophy?

Athletes who perform high-volume endurance training, such as distance runners and cyclists, can develop a physiologic form of eccentric remodeling. This is generally benign and regresses when training decreases. Pathologic eccentric hypertrophy in patients with disease looks different on imaging and carries different prognostic meaning. Cardiologists distinguish these based on history, imaging features, and sometimes cardiac MRI.

How often should I get an echocardiogram if I have eccentric hypertrophy?

It depends on the cause and severity. For asymptomatic valvular regurgitation we often repeat imaging every six to twelve months. For hypertension-driven remodeling, annual imaging is reasonable while we optimize therapy. For established heart failure, imaging is driven by symptoms and clinical changes. Your cardiologist should set a schedule that matches your specific situation.

Does eccentric hypertrophy cause symptoms?

Early on, usually not. That is part of why it matters to catch it on imaging before symptoms appear. As remodeling progresses, patients may develop shortness of breath with exertion, fatigue, palpitations, and eventually signs of heart failure like leg swelling or difficulty breathing when lying flat. New or worsening symptoms warrant prompt cardiology evaluation.

References

1. Gaasch WH, Zile MR. Left Ventricular Structural Remodeling in Health and Disease. J Am Coll Cardiol. 2011.

2. Halliday BP, Prasad SK. The Interstitium in the Hypertrophied Heart. JACC Cardiovasc Imaging. 2019.

3. Leache L, et al. Pharmacotherapy for Hypertension-Induced Left Ventricular Hypertrophy. Cochrane Database Syst Rev. 2021.

4. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in Ventricular Remodelling. Lancet. 2006.

5. Ha ET, Ivanov A, Yeboah J, et al. Relation of Left Ventricular Hypertrophy Subtype to Long-Term Mortality (MESA). Am J Cardiol. 2022.

6. Velagaleti RS, Gona P, Pencina MJ, et al. Left Ventricular Hypertrophy Patterns and Incidence of Heart Failure With Preserved Versus Reduced Ejection Fraction. Am J Cardiol. 2014.

7. Paoletti E, et al. Associations of LVH and Geometry With Adverse Outcomes in CKD and Hypertension. Clin J Am Soc Nephrol. 2016.

8. Guzik BM, et al. Echocardiography Predictors of Survival in Hypertensive Patients With LVH. Am J Hypertens. 2021.

9. Katz DH, et al. Eccentric Versus Concentric LVH in HFpEF. Am J Cardiol. 2013.